#South Korea #Samsung Biologics #Incheon #water security #Environmental Stewardship

Samsung Biologics Achieves 'A' Rating in Water Security

In Incheon, South Korea, December 10, 2025 - Samsung Biologics, a prominent contract development and manufacturing organization (CDMO), recently announced its commendation for water security from the Carbon Disclosure Project (CDP). This accolade comes two years following the company's engagement in the CDP's environmental assessments, reflecting its commitment to sustainability and environmental stewardship.

CDP and the Water Security Rating

The CDP is an organization that invites major global companies to disclose information regarding their environmental impact. By participating in these assessments, companies can earn recognition for their sustainability efforts. Samsung Biologics achieved the coveted 'A' rating in Water Security, a notable increase from its previous year's rating. This rating places the firm in an elite category, as only about 2% of companies evaluated by the CDP receive such a distinction.

Essentially, the CDP's 'A List' is a prestigious ranking awarded to organizations that demonstrate outstanding leadership in environmental practices. This year, Samsung Biologics was recognized for establishing concrete objectives related to natural capital strategies, water pollution control, and effective water reuse methods. Not only did the company set ambitious goals, but it also exhibited a high degree of accuracy in reporting important data concerning water usage and management, including intake, discharge, and overall consumption.

A Commitment to Environmental Stewardship

"This recognition exemplifies our unwavering commitment to the environmental, social, and governance (ESG) strategies outlined by our global clients," stated John Rim, CEO and President of Samsung Biologics. "We are dedicated to achieving carbon neutrality and enhancing our management of water resources moving forward."

As an active participant in the Sustainable Markets Initiative (SMI) Health Systems Task Force, Samsung Biologics leads the Supply Chains Working Group, promoting industry-wide ESG efforts as a trusted and sustainable CDMO partner. The company has set an ambitious goal of transitioning entirely to renewable energy by 2050, and it is continually exploring ways to manage natural resources more effectively and minimize its environmental footprint throughout its operations.

The Role of Samsung Biologics in the Biologics Sector

Founded in 2000, Samsung Biologics has grown to be a leading player in the biopharmaceutical manufacturing sector, boasting a combined biomanufacturing capacity of 784,000 liters across five state-of-the-art facilities. It utilizes cutting-edge technologies and expertise to manufacture a wide range of biologics, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapies.

By implementing its ExellenS™ framework across its manufacturing network, the company ensures standardized designs, unified operational processes, and enhanced digitalization, promoting efficiency and quality. Furthermore, Samsung Biologics has commercial offices in countries such as Korea, the U.S., and Japan, facilitating support for clients across the APAC region and beyond.

The organization remains dedicated to ongoing investments that enhance operational and quality excellence, ensuring the on-time delivery of high-quality products while making informed, sustainable business decisions that benefit wider society and global health. To learn more about their initiatives and impact, visit Samsung Biologics.